

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Company Registration No.91120000103100784F)
(Incorporated in the People's Republic of China)

RESPONSE TO SGX-ST'S QUERY ON UNAUDITED INTERIM RESULTS FOR THE 3-MONTH ENDED 31 MARCH 2023

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company", and together with its subsidiaries, the "Group") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

All capitalised terms used herein, unless the context otherwise requires, shall bear the meanings ascribed to them in the 1Q2023 Results Announcement (as defined below).

The Company has received a query from the Singapore Exchange Securities Trading Limited (the "SGX-ST") regarding the Company's unaudited interim results for the 3-month period ended 31 March 2023 ("1Q2023") announced on 28 April 2023 (the "1Q2023 Results Announcement"). The Company's response to the query of the SGX-ST are set out below:-

SGX-ST's Query

We note that the related party transactions disclosed at Note 25 of the financial statements are significantly higher than the interested person transactions disclosed at page 26 of the Company's financial results. Please explain the differences and provide details of the related party transactions to support any explanation that they are not interested person transactions.

Company's Response:

On pages 23 and 24 of the 1Q2023 Results Announcement, the disclosure under "related parties transactions" stated in Note 25 represents the aggregation of all related parties transactions for 1Q2023 (including the interested person transactions disclosed at pages 24 to 26 of the 1Q2023 Results Announcement) comprising:

- (i) sale of goods to associates and related companies;
- (ii) purchase of goods from associates and related companies;
- (iii) interest income from an associate;
- (iv) interest expense payable to an associate;
- (v) rental income from an associate and related companies; and
- (vi) rental expenses to related companies.

However, on pages 24 to 26 of the 1Q2023 Results Announcement, the "Interested Person Transactions disclosure" stated in Note 26 pertains only to the interest payable on the credit facilities provided by Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) (being an associate of the Company) which amounts to RMB347,000 (i.e., item (iv) above). The items (i) to (iii) and items (v) and (vi) above are excluded from disclosure in Note 26 as the respective amounts thereof

are individually less than S\$100,000 and are therefore not subject to the disclosure requirement under Rule 907 of the Listing Manual of the SGX-ST.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
17 May 2023